OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and is an essential osteoclast differentiation factor in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor B ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“In the absence of RANK or RANKL, osteoclasts cannot form, function, or survive (62-64, 110, 111).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“RANK and RANKL knockout mice were virtual phenocopies of each other (62)(63)(64), which indicated that RANK and RANKL had few if any roles beyond their mutual interactions.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Another unexpected phenotype found in RANK and RANKL knockout mice was the total lack of lymph nodes (62,64).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Examination of mice genetically deficient in RANKL, RANK, or OPG also revealed no overt dendritic cell defects (62,64,170).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P., Montgomery, C., Geske, R., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 2,016
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Self-citationManolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,668
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.
Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E., Gliniak, B. C., Park, L. S., Ziegler, S. F., Williams, D. E., Ware, C. B., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.5.1955 · Cited by 1,555
c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling
Grigoriadis, A. E., Wang, Z.-Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., & Wagner, E. F. (1994) · Science · doi:10.1126/science.7939685 · Cited by 1,260
Cited by
Items 401–500 of 1,030
The pathogenesis of the bone disease of multiple myeloma
Edwards, C. M., Zhuang, J., & Mundy, G. R. (2008) · Bone · doi:10.1016/j.bone.2008.01.027 · Cited by 185
“The critical role of these TNF family members is highlighted by in vivo studies where mice deficient in RANK or RANKL have extensive osteopetrosis due to a lack of functional osteoclasts [17,18], whereas OPG knock-out mice have severe osteoporosis [19].”
BackgroundCrotti, T. N., Smith, M. D., Weedon, H., Ahern, M. J., Findlay, D. M., Kraan, M., Tak, P. P., & Haynes, D. R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.12.1047 · Cited by 186
Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand
Li, J.-Y., Tawfeek, H., Bedi, B., Yang, X., Adams, J., Gao, K. Y., Zayzafoon, M., Weitzmann, M. N., & Pacifici, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013492108 · Cited by 186
“S3) whereby ovx increases the number of activated CD40L-expressing T cells that promote the expression of M-CSF and RANKL by SCs and down-regulates the SC production of OPG.”
BackgroundInfluentialAshcroft, A. J., Cruickshank, S. M., Croucher, P. I., Perry, M. J., Rollinson, S., Lippitt, J. M., Child, J. A., Dunstan, C., Felsburg, P. J., Morgan, G. J., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00326-1 · Cited by 182
Self-citationYamamoto, N., Sakai, F., Kon, S., Morimoto, J., Kimura, C., Yamazaki, H., Okazaki, I., Seki, N., Fujii, T., & Uede, T. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17778 · Cited by 187
The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis
Haynes, D. R., Crotti, T. N., Potter, A. E., Loric, M., Atkins, G. J., Howie, D. W., & Findlay, D. M. (2001) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.83b6.0830902 · Cited by 186
PATHOGENESIS OF RHEUMATOID ARTHRITIS
Panayi, G. S., Corrigall, V. M., & Pitzalis, C. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70204-0 · Cited by 189
Evaluation of Pharmaceuticals With a Novel 50-Hour Animal Model of Bone Loss
Tomimori, Y., Mori, K., Koide, M., Nakamichi, Y., Ninomiya, T., Udagawa, N., & Yasuda, H. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090217 · Cited by 184
“However, the importance of RANKL has been much more shown in bone metabolism than in the immune system.((24))”
BackgroundKohli, S., & Kohli, V. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.83401 · Cited by 167
“[15-18] RANKL is identified to belong to the tumor necrosis factor (TNF) family and has been recognized to be the only cytokine to play an essential role in bone metabolism as it regulates the development, maintenance and activation of osteoclasts.[16,19,20] The RANKL gene encodes a 316AA protein which is structurally…”
BackgroundHeim, M., Frank, O., Kampmann, G., Sochocky, N., Pennimpede, T., Fuchs, P., Hunziker, W., Weber, P., Martin, I., & Bendik, I. (2004) · Endocrinology · doi:10.1210/en.2003-1014 · Cited by 178
“RANKL is essential in the maturation and activity of osteoclasts (40).”
Genetic Disorders of the Skeleton: A Developmental Approach
Kornak, U., & Mundlos, S. (2003) · The American Journal of Human Genetics · doi:10.1086/377110 · Cited by 180
“Whereas RANK knockouts are severely osteopetrotic, OPG knockouts are osteoporotic, which highlights the crucial role of this signaling system for bone remodeling (Simonet et al. 1997; Kong et al. 1999).”
BackgroundWang, L., Zhao, R., Shi, X., Wei, T., Halloran, B. P., Clark, D. J., Jacobs, C. R., & Kingery, W. S. (2009) · Bone · doi:10.1016/j.bone.2009.04.203 · Cited by 179
“the minimal concentration of soluble RANKL (4 ng/ml) required to induce osteoclastic differentiation.[37,38] Furthermore, we failed to observe any TRAP+ multinucleated cells in a co-culture of SP stimulated BMSCs and RAW 264.”
BackgroundArmstrong, A. P., Miller, R. E., Jones, J. C., Zhang, J., Keller, E. T., & Dougall, W. C. (2008) · The Prostate · doi:10.1002/pros.20678 · Cited by 180
“The TNF ligand superfamily member RANKL is critical for formation, function, and survival of osteoclasts [10,11] and exerts its action through binding and activation of its receptor RANK [12,13], which is expressed on the surface of myeloid osteoclast precursors [14].”
The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis
Wada, T., Nakashima, T., Oliveira-dos-Santos, A. J., Gasser, J., Hara, H., Schett, G., & Penninger, J. M. (2005) · Nature Medicine · doi:10.1038/nm1203 · Cited by 182
“The tumor necrosis factor receptor (TNFR) superfamily member RANK (receptor activator of NF-κB; also called TNFRSF11A) and its ligand RANKL (also called osteoprotegerin ligand, TRANCE, ODF or TNFSF11) are the key regulators of bone metabolis”
BackgroundSelf-citationNagy, V., & Penninger, J. M. (2015) · Gerontology · doi:10.1159/000371845 · Cited by 171
Self-citationFujita, K.-I., & Janz, S. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-71 · Cited by 178
“Wnt/ -catenin signaling has been reported to attenuate osteoclastogenesis by down modulating the important regulator of bone homeostasis, RANKL [47], in osteoprogenitors [14].”
BackgroundChemokines in Physiological and Pathological Bone Remodeling
Brylka, L. J., & Schinke, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02182 · Cited by 172
“Most importantly, in vitro formation of bone-resorbing osteoclasts does not occur in the absence of RANKL, and mice deficient for RANKL display severe osteopetrosis as they do not develop osteoclasts (9, 10).”
BackgroundRANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
Infante, M., Fabi, A., Cognetti, F., Gorini, S., Caprio, M., & Fabbri, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1001-2 · Cited by 180
“Specifically, it is essential for different processes affecting immune regulation, such as interaction between T cells and dendritic cells [14], lymphocyte development, lymph node organogenesis [15], and thymic development [16].”
BackgroundCells of the synovium in rheumatoid arthritis. Osteoclasts.
Schett, G. A. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2110 · Cited by 214
“Very similar results were also obtained with therapeutic administration of potent bisphosphonates like zolendronic acid and osteoprotegerin, a decoy receptor and thus negative regulator of RANKL [16,25-29].”
BackgroundResultGastric Acid, Calcium Absorption, and Their Impact on Bone Health
Kopic, S., & Geibel, J. P. (2013) · Physiological Reviews · doi:10.1152/physrev.00015.2012 · Cited by 176
“In accordance with this model, RANKL-deficient animals develop osteopetrosis because of insufficient osteoclasts activation (592).”
Hofbauer, L. C., & Heufelder, A. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6702 · Cited by 169
The Association of Notch2 and NF-κB Accelerates RANKL-Induced Osteoclastogenesis
Fukushima, H., Nakao, A., Okamoto, F., Shin, M., Kajiya, H., Sakano, S., Bigas, A., Jimi, E., & Okabe, K. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00299-08 · Cited by 178
“The in vivo significance of the RANKL-RANK signaling pathway has been verified in mice by targeted disruption of either of the associated genes, which results in severe osteopetrosis and a total lack of osteoclasts (14, 29).”
BackgroundSedger, L. M., Glaccum, M. B., Schuh, J. C. L., Kanaly, S. T., Williamson, E., Kayagaki, N., Yun, T., Smolak, P. J., Le, T., Goodwin, R. G., et al. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200208)32:8<2246::aid-immu2246>3.0.co;2-6 · Cited by 208
MITF and PU.1 Recruit p38 MAPK and NFATc1 to Target Genes during Osteoclast Differentiation
Sharma, S. M., Bronisz, A., Hu, R., Patel, K., Mansky, K. C., Sif, S., & Ostrowski, M. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609723200 · Cited by 175
Patsch, J. M., Kiefer, F. W., Varga, P., Pail, P., Rauner, M., Stupphann, D., Resch, H., Moser, D., Zysset, P. K., Stulnig, T. M., et al. (2011) · Metabolism · doi:10.1016/j.metabol.2009.11.023 · Cited by 169
“Although not tested in this study, alterations in the equilibrium of the receptor activator of nuclear factor κB ligand and its endogenous opponent osteoprotegerin could be of pivotal importance in obesity-associated osteoclast activation [47].”
BackgroundLandewé, R., van der Heijde, D., Klareskog, L., van Vollenhoven, R., & Fatenejad, S. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22143 · Cited by 177
Maintaining homeostatic control of periodontal bone tissue
Hathaway‐Schrader, J. D., & Novince, C. M. (2021) · Periodontology 2000 · doi:10.1111/prd.12368 · Cited by 167
Osteopontin: a bridge between bone and the immune system
Gravallese, E. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19190 · Cited by 161
“One well described story is that of the receptor-activator of NF-κB ligand (RANKL)/osteoprotegerin (OPG) system, which plays a role in the interaction between dendritic cells and T cells in the immune system and is the critical regulatory system for bone remodeling under physiologic conditions (1, 2).”
BackgroundA potent analog of 1α,25-dihydroxyvitamin D 3 selectively induces bone formation
Shevde, N. K., Plum, L. A., Clagett-Dame, M., Yamamoto, H., Pike, J. W., & DeLuca, H. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202471299 · Cited by 176
Expression of TRAIL and TRAIL receptors in normal and malignant tissues
DANIELS, R. A., TURLEY, H., KIMBERLEY, F. C., LIU, X. S., MONGKOLSAPAYA, J., CH'EN, P., XU, X. N., JIN, B., PEZZELLA, F., & SCREATON, G. R. (2005) · Cell Research · doi:10.1038/sj.cr.7290311 · Cited by 173
RANKL/RANK control Brca1 mutation-driven mammary tumors
Sigl, V., Owusu-Boaitey, K., Joshi, P. A., Kavirayani, A., Wirnsberger, G., Novatchkova, M., Kozieradzki, I., Schramek, D., Edokobi, N., Hersl, J., et al. (2016) · Cell Research · doi:10.1038/cr.2016.69 · Cited by 175
Self-citationRANKL as the master regulator of osteoclast differentiation
Takayanagi, H. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01191-1 · Cited by 175
RANK–RANKL signalling in cancer
Renema, N., Navet, B., Heymann, M.-F., Lezot, F., & Heymann, D. (2016) · Bioscience Reports · doi:10.1042/bsr20160150 · Cited by 161
Kanematsu, M., Sato, T., Takai, H., Watanabe, K., Ikeda, K., & Yamada, Y. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.7.1321 · Cited by 174
“(15) RANK, a member of the TNF receptor family of proteins, recently has been identified on osteoclast progenitors as a receptor for RANKL and was shown to mediate RANKL-induced osteoclast differentiation and activation.”
BackgroundIdris, A. I., Sophocleous, A., Landao-Bassonga, E., Canals, M., Milligan, G., Baker, D., van't Hof, R. J., & Ralston, S. H. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.07.006 · Cited by 179
Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
Cao, J., Venton, L., Sakata, T., & Halloran, B. P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.2.270 · Cited by 173
Evolution of the mammary gland from the innate immune system?
Vorbach, C., Capecchi, M. R., & Penninger, J. M. (2006) · BioEssays · doi:10.1002/bies.20423 · Cited by 171
Self-citationPalmqvist, P., Lundberg, P., Persson, E., Johansson, A., Lundgren, I., Lie, A., Conaway, H. H., & Lerner, U. H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510160200 · Cited by 166
Fu, Q., Manolagas, S. C., & O'Brien, C. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00356-06 · Cited by 166
“exhibit disrupted mammary gland development (12, 31).”
BackgroundHigh d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis
Wittrant, Y., Gorin, Y., Woodruff, K., Horn, D., Abboud, H. E., Mohan, S., & Abboud-Werner, S. L. (2008) · Bone · doi:10.1016/j.bone.2008.02.006 · Cited by 164
“Receptor Activator of Nuclear Factor kappaB Ligand (NF-κB) is a key factor for differentiation of monocyte/macrophage osteoclast precursors into multinucleated osteoclasts and for activation of mature osteoclasts [16–18].”
BackgroundControl of RANKL gene expression
O'Brien, C. A. (2010) · Bone · doi:10.1016/j.bone.2009.08.050 · Cited by 162
“It has been more than a decade since the cytokine known as receptor activator of NFκB ligand (RANKL) was shown to be essential for osteoclast differentiation in mice [1].”
BackgroundInflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function
Charles, J. F., Hsu, L.-Y., Niemi, E. C., Weiss, A., Aliprantis, A. O., & Nakamura, M. C. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60920 · Cited by 164
TRAF‐Mediated TNFR‐Family Signaling
Ha, H., Han, D., & Choi, Y. (2009) · Current Protocols in Immunology · doi:10.1002/0471142735.im1109ds87 · Cited by 154
“Kong, Y.Y., Yoshida, H., Sarosi, I., Tan, H.L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A.J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C.R., Lacey, D.L., Mak, T.W., Boyle, W.J., and Penninger, J.M. 1999.”
InfluentialKiviranta, R., Morko, J., Alatalo, S. L., NicAmhlaoibh, R., Risteli, J., Laitala-Leinonen, T., & Vuorio, E. (2005) · Bone · doi:10.1016/j.bone.2004.09.020 · Cited by 172
The insulin-like growth factor-I gene and osteoporosis: A critical appraisal
Niu, T., & Rosen, C. J. (2005) · Gene · doi:10.1016/j.gene.2005.07.016 · Cited by 168
Signaling crosstalk between RANKL and interferons in osteoclast differentiation.
Takayanagi, H., Kim, S., & Taniguchi, T. (2002) · Arthritis Research · doi:10.1186/ar581 · Cited by 181
Coleman, R. E. (2000) · The Oncologist · doi:10.1634/theoncologist.5-6-463 · Cited by 162
Heltemes-Harris, L. M., Willette, M. J. L., Ramsey, L. B., Qiu, Y. H., Neeley, E. S., Zhang, N., Thomas, D. A., Koeuth, T., Baechler, E. C., Kornblau, S. M., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101947 · Cited by 161
“The most strongly derepressed of all genes in our analysis is Tnfsf11 (44-fold increase in expression), which encodes RANKL, a factor known to promote progenitor B cell proliferation (Kong et al., 1999).”
BackgroundRecent advances in osteoclast biology and pathological bone resorption.
Blair, H. C., & Athanasou, N. A. (2004) · PubMed · doi:10.14670/hh-19.189 · Cited by 168
Baud'Huin, M., Renault, R., Charrier, C., Riet, A., Moreau, A., Brion, R., Gouin, F., Duplomb, L., & Heymann, D. (2010) · The Journal of Pathology · doi:10.1002/path.2684 · Cited by 159
“However, RANKL knock-out mice completely lack TRAPpositive immature and mature multinucleated osteoclasts [12].”
BackgroundRole of nuclear factor‐κB in the immune system and bone
Jimi, E., & Ghosh, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00329.x · Cited by 163
“The in vivo significance of the RANKL–RANK-signaling pathway has been verified by the observations that targeting disruption of either gene in mice results in severe osteopetrosis and a total lack of osteoclasts (26, 27).”
BackgroundNADPH oxidase 4 limits bone mass by promoting osteoclastogenesis
Goettsch, C., Babelova, A., Trummer, O., Erben, R. G., Rauner, M., Rammelt, S., Weissmann, N., Weinberger, V., Benkhoff, S., Kampschulte, M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67603 · Cited by 161
“RANKL binding initiates osteoclast differentiation and activation (2) and is responsible for the induction of osteoclastic genes like tartrate-resistant acid phosphatase (TRAP) and cathepsin K (3).”
Targeted therapies for non-small cell lung cancer
Dempke, W. C. M., Suto, T., & Reck, M. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.10.012 · Cited by 164
“Deletion of the RANK or RANKL gene in mice resulted in severe osteopetrosis and lack of osteoclast formation [131].”
BackgroundLigand Activation of ERRα by Cholesterol Mediates Statin and Bisphosphonate Effects
Wei, W., Schwaid, A. G., Wang, X., Wang, X., Chen, S., Chu, Q., Saghatelian, A., & Wan, Y. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.010 · Cited by 161
The Osteoclast in Bone Metastasis: Player and Target
Maurizi, A., & Rucci, N. (2018) · Cancers · doi:10.3390/cancers10070218 · Cited by 160
Infantile Malignant, Autosomal Recessive Osteopetrosis: The Rich and The Poor
Villa, A., Guerrini, M. M., Cassani, B., Pangrazio, A., & Sobacchi, C. (2009) · Calcified Tissue International · doi:10.1007/s00223-008-9196-4 · Cited by 166
“This mild deficit in patients is clearly in contrast with the more severe phenotype reported in the corresponding mouse model, where a block in T cell differentiation at the pre-TCR stage and B cell differentiation at the proB-preB stage, together with a complete absence of lymph nodes, has been described [78, 79].”
BackgroundResultIdentification of cell cycle–arrested quiescent osteoclast precursors in vivo
Mizoguchi, T., Muto, A., Udagawa, N., Arai, A., Yamashita, T., Hosoya, A., Ninomiya, T., Nakamura, H., Yamamoto, Y., Kinugawa, S., et al. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200806139 · Cited by 164
“RANKL-defi cient (RANKL / ) mice also exhibit severe osteopetrosis because of a lack of osteoclasts ( Kong et al., 1999 ; Suda et al., 1999 ; Arron and Choi, 2000 ; Hofbauer et al., 2000 ; Takahashi et al., 2002 ; Boyle et al., 2003 ).”
Self-citationXing, L., Bushnell, T. P., Carlson, L., Tai, Z., Tondravi, M., Siebenlist, U., Young, F., & Boyce, B. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1200 · Cited by 165
“for osteoclast formation, but also appear to regulate the activity of mature osteoclasts as well as dendritic cell functions and T cell activation.((6)) Anti-RANK antibody and”
BackgroundInfluentialNosaka, K., Miyamoto, T., Sakai, T., Mitsuya, H., Suda, T., & Matsuoka, M. (2002) · Blood · doi:10.1182/blood.v99.2.634 · Cited by 168
Bendixen, A. C., Shevde, N. K., Dienger, K. M., Willson, T. M., Funk, C. D., & Pike, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041493198 · Cited by 161
Comparative Tolerability of Drug Therapies for Hypercalcaemia of Malignancy
Zojer, N., Keck, A. V., & Pecherstorfer, M. (1999) · Drug Safety · doi:10.2165/00002018-199921050-00004 · Cited by 167
Roles of osteoclasts in alveolar bone remodeling
Omi, M., & Mishina, Y. (2022) · genesis · doi:10.1002/dvg.23490 · Cited by 263
“and bone remodeling as deletion of Rankl in mice leads to severe osteopetrosis (Kong et al., 1999).”
BackgroundFine-tuning of dendritic cell biology by the TNF superfamily
deLuca, L. S., & Gommerman, J. L. (2012) · Nature reviews. Immunology · doi:10.1038/nri3193 · Cited by 184
Regulation of Embryonic and Postnatal Development by the CSF-1 Receptor
Chitu, V., & Stanley, E. R. (2017) · Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.10.004 · Cited by 161
“, 1998), deficiency of which also resulted in osteopetrosis (Kong et al., 1999).”
BackgroundCannabinoid receptors and the regulation of bone mass
Bab, I., & Zimmer, A. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707593 · Cited by 161
“…ligand, osteoprotegerin, macrophage colony-stimulating factor and interleukin 6, which are derived from neighbouring stromal cells, including osteoblasts and their precursors (Poli et al., 1994; Simonet et al., 1997; Bucay et al., 1998; Lacey et al., 1998; Kong et al., 1999; Suda et al., 2001).”
BackgroundChronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice
Dai, J., Lin, D., Zhang, J., Habib, P., Smith, P., Murtha, J., Fu, Z., Yao, Z., Qi, Y., & Keller, E. T. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10483 · Cited by 157
“The effect of recombinant human (1-84) or”
BackgroundEnomoto, H., Shiojiri, S., Hoshi, K., Furuichi, T., Fukuyama, R., Yoshida, C. A., Kanatani, N., Nakamura, R., Mizuno, A., Zanma, A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302457200 · Cited by 161
Robust B Cell Immunity but Impaired T Cell Proliferation in the Absence of CD134 (OX40)
Pippig, S. D., Peña-Rossi, C., Long, J., Godfrey, W. R., Fowell, D. J., Reiner, S. L., Birkeland, M. L., Locksley, R. M., Barclay, A. N., & Killeen, N. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6520 · Cited by 163
Osteoporosis in patients with chronic kidney diseases: A systemic review
Hsu, C.-Y., Chen, L.-R., & Chen, K.-H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186846 · Cited by 162
“RANK-L knockout mice had been demonstrated to develop severe osteoporosis as well as defective T and B lymphocytes differentiation [133].”
BackgroundOsteoimmunology: Inflammatory osteolysis and regeneration of the alveolar bone
Gruber, R. (2019) · Journal of Clinical Periodontology · doi:10.1111/jcpe.13056 · Cited by 159
Osteoprotegerin ligand: a regulator of immune responses and bone physiology
Kong, Y.-Y., Boyle, W. J., & Penninger, J. M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01718-7 · Cited by 162
Self-citationXu, J., Tan, J. W., Huang, L., Gao, X.-H., Laird, R., Liu, D., Wysocki, S., & Zheng, M. H. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.11.2178 · Cited by 160
Newberry, R. D., & Lorenz, R. G. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00282.x · Cited by 153
“LTa (71) LTbR (73) NiK ? ? (76) aly/aly + (77, 78) Relb ? ? (80) Ikka ? ? ? (81) LTb + ? ? CLN (75) NF-kB2 + ? ? (79) Jak3 + ? ? (93) IL7Ra + (86, 89) IL7 ? ? ? (90) CXCL13 +/+ ? ? CLN, FLN (40) CXCR5 +/+ ? ? CLN, FLN, PoLN (82) gc + ? BLN, ALN (86, 88) RORgt (6, 7) CCR9 deficient (CCL25-intrakine expression) ? ? ? (1…”
The Critical Role of IL-34 in Osteoclastogenesis
Chen, Z., Buki, K., Vääräniemi, J., Gu, G., & Väänänen, H. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018689 · Cited by 154
“Previous studies have shown that RANKL, which is another key factor for osteoclastogenesis, can be produced by activated lymphocytes [4,20].”
Do RANKL inhibitors (denosumab) affect inflammation and immunity?
Ferrari, S., & Ferrari, S. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1326-y · Cited by 170
“Moreover, when OPG or RANKL are added to wild-type murine T-cell cultures, their proliferation and production of cytokines remain unaffected, suggesting that RANKL signaling is not crucial for mature T-cell functions [18].”
BackgroundInfluentialHuman Parathyroid Hormone 1–34 Reverses Bone Loss in Ovariectomized Mice
Alexander, J. M., Bab, I., Fish, S., Müller, R., Uchiyama, T., Gronowicz, G., Nahounou, M., Zhao, Q., White, D. W., Chorev, M., et al. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.9.1665 · Cited by 165
Fakruddin, J. M., & Laurence, J. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304676200 · Cited by 175
The development of intestinal lymphoid tissues at the interface of self and microbiota
Eberl, G., & Lochner, M. (2009) · Mucosal Immunology · doi:10.1038/mi.2009.114 · Cited by 177
Modulating the intestinal immune system: the role of lymphotoxin and GALT organs
Spahn, T. W., & Kucharzik, T. (2004) · Gut · doi:10.1136/gut.2003.023671 · Cited by 180
Kim, K., Cho, M., Lee, S., Oh, H.-J., Kang, C.-M., Ju, J. H., Min, S., Cho, Y. G., Park, S., & Kim, H. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.03.004 · Cited by 175
TRAF‐Mediated TNFR‐Family Signaling
Arron, J. R., Walsh, M. C., & Choi, Y. (2002) · Current Protocols in Immunology · doi:10.1002/0471142735.im1109ds51 · Cited by 157
Anastasilakis, A. D., Pepe, J., Napoli, N., Palermo, A., Magopoulos, C., Khan, A. A., Zillikens, M. C., & Body, J.-J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab888 · Cited by 157
NFATc1 regulation of the human β3 integrin promoter in osteoclast differentiation
Crotti, T. N., Flannery, M. R., Walsh, N. C., Fleming, J. D., Goldring, S. R., & McHugh, K. P. (2006) · Gene · doi:10.1016/j.gene.2005.12.012 · Cited by 157
Heider, U., Langelotz, C., Jakob, C., Zavrski, I., Fleissner, C., Eucker, J., Possinger, K., Hofbauer, L. C., & Sezer, O. (2003) · PubMed · Cited by 172
Grant, E. P., Picarella, D., Burwell, T., Delaney, T., Croci, A., Avitahl, N., Humbles, A. A., Gutierrez-Ramos, J.-C., Briskin, M., Gerard, C., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020205 · Cited by 158
“In addition, OPGL expression in the joints of C5aR / mice remained at baseline levels, reflecting a failure to activate a key pathway believed to regulate osteoclastogenesis and bone resorption in arthritis (30, 31).”
BackgroundAdvances in understanding the leukaemia microenvironment
Tabe, Y., & Konopleva, M. Y. (2014) · British Journal of Haematology · doi:10.1111/bjh.12725 · Cited by 172
Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization
Miyamoto, K., Yoshida, S., Kawasumi, M., Hashimoto, K., Kimura, T., Sato, Y., Kobayashi, T., Miyauchi, Y., Hoshi, H., Iwasaki, R., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101890 · Cited by 149
“BM cavities are formed by osteoclasts, which are bone resorbing multinuclear cells, and loss of osteoclasts results in loss of BM cavities (Yoshida et al., 1990; Grigoriadis et al., 1994; Kong et al., 1999).”
Self-citationBone disease and skeletal complications in patients with β thalassemia major
Haidar, R., Musallam, K. M., & Taher, A. T. (2010) · Bone · doi:10.1016/j.bone.2010.10.173 · Cited by 176
The Central Regulation of Bone Mass, The First Link between Bone Remodeling and Energy Metabolism
Karsenty, G., & Oury, F. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1030 · Cited by 142
Molecular mechanisms underlying osteoclast formation and activation
Troen, B. R. (2003) · Experimental Gerontology · doi:10.1016/s0531-5565(03)00069-x · Cited by 181
Moreno, J. L., Kaczmarek, M., Keegan, A. D., & Tondravi, M. (2003) · Blood · doi:10.1182/blood-2002-11-3437 · Cited by 150
Wick, G., Jansen‐Dürr, P., Berger, P., Blasko, I., & Grubeck‐Loebenstein, B. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00489-2 · Cited by 176
Interactions between immune and bone cells: new insights with many remaining questions
Lorenzo, J. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11089 · Cited by 156
“This is most clearly demonstrated in RANKL/OPG-L–deficient (22) and RANKdeficient mice (23, 24).”
BackgroundOsteoclast signalling pathways
Blair, H. C., Robinson, L. J., & Zaidi, M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.077 · Cited by 173
Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota
Nagashima, K., Sawa, S., Nitta, T., Tsutsumi, M., Okamura, T., Penninger, J. M., Nakashima, T., & Takayanagi, H. (2017) · Nature Immunology · doi:10.1038/ni.3732 · Cited by 154
Self-citationChen, X., Zhi, X., Wang, J., & Su, J. (2018) · Bone Research · doi:10.1038/s41413-018-0035-6 · Cited by 154
Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget’s disease of bone.
Menaa, C., Reddy, S. V., Kurihara, N., Maeda, H., Anderson, D., Cundy, T., Cornish, J., Singer, F. R., Bruder, J. M., & Roodman, G. D. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9133 · Cited by 154
“In vivo studies have shown that mice lacking RANKL developed severe osteopetrosis (11).”
BackgroundOsteoprotegerin: Multiple partners for multiple functions
Baud’huin, M., Duplomb, L., Teletchea, S., Lamoureux, F., Ruiz-Velasco, C., Maillasson, M., Redini, F., Heymann, M.-F., & Heymann, D. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.06.001 · Cited by 153
“It has been shown that mice lacking Rankl did not have osteoclasts and suffered from severe osteopetrosis (Kong et al. 1999).”
BackgroundThe role of TRAF6 in signal transduction and the immune response
Kobayashi, T., Walsh, M. C., & Choi, Y. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.09.001 · Cited by 170
Kong, Y., Boyle, W. J., & Penninger, J. M. (1999) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1999.00815.x · Cited by 152
Self-citation
Metadata
- Authors
- Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., & Penninger, J. M.
- Affiliations
- University of Toronto (CA)
- Amgen (United States) (US)
- Corresponding author
- Penninger, Josef M.
- Venue
- Nature
- Published
- 1999-01
- Volume
- 397
- Issue
- 6717
- Pages
- 315-323
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1534645474
- Cited by
- 3,351
- References
- 52
- Citations by year
- 2026: 27 · 2025: 47 · 2024: 58 · 2023: 71 · 2022: 88 · 2021: 114 · 2020: 121 · 2019: 102 · 2018: 95 · 2017: 115 · 2016: 107 · 2015: 125 · 2014: 119 · 2013: 138 · 2012: 162
- FWCI
- 49.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- osteoprotegerin ligand, RANKL, osteoclastogenesis, osteopetrosis, tooth eruption, lymphocyte development, dendritic cells, T cell development, B cell development, osteoblasts
- MeSH terms
- Animals, B-Lymphocytes, Carrier Proteins, Cell Differentiation, Cells, Cultured, Dendritic Cells, Female, Embryonic and Fetal Development, Growth Substances, Hematopoiesis, Extramedullary, Hematopoietic Stem Cells, Lymph Nodes, Lymphocyte Activation, Lymphocytes, Male, Membrane Glycoproteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Molecular Sequence Data, Osteoclasts, Osteogenesis, Osteopetrosis, T-Lymphocytes, Thymus Gland, Cytokines, Mutagenesis, Bone Remodeling, Gene Targeting, Leukopoiesis, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.